Phuturdex › Diseases › Germ cell and embryonal neoplasms
Drugs in development · updated 30 October 2026
Germ cell and embryonal neoplasms: drugs in development
As of 30 October 2026 there are 24 active clinical trials (recruiting or ongoing, phases I–III) on 35 drugs for germ cell and embryonal neoplasms. 6 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Thromboprophylaxis | III | 1 | NCT05874063 |
| ZanzalintinibXL092 | I–II | 1 | NCT06937866 |
| G207 | I | 1 | NCT03911388 |
| XmAb541 | I | 1 | NCT06276491 |
| ZW251 | I | 1 | NCT07164313 |
| SGT-53 | Early I | 1 | NCT07017816 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| EtoposideAvopef®, Etopophos Preservative Free® | III | 9 | NCT02582697 |
| CisplatinCis Platinum, Cisplatine | III | 6 | NCT02582697 |
| BleomycinBleomicina, Blenoxane® | III | 4 | NCT02582697 |
| CarboplatinCarboplatine, Paraplatin | III | 3 | NCT03067181 |
| PaclitaxelTaxol, Paxlitaxel | III | 3 | NCT02375204 |
| Ifosfamide | III | 2 | NCT02375204 |
| FilgrastimRecombinant Human Granulocyte Colony-Stimulating Factor, Neupogen | III | 1 | NCT02582697 |
| CyclophosphamideCyclophosphamid, Cytoxan | I–II | 3 | NCT05092451 |
| FludarabineFludara, FLUDARABIN | I–II | 2 | NCT05092451 |
| MesnaUromitexan, Mesnex® | II | 2 | NCT01873326 |
| CelecoxibCelebrex Capsule, Elyxyb® | II | 1 | NCT02574728 |
| DocetaxelTaxotere, Beizray® | I–II | 1 | NCT07850973 |
| DurvalumabMEDI4736, Imfinzi® | II | 1 | NCT03158064 |
| GemcitabineGemcitabin, Gemzar | I–II | 1 | NCT07850973 |
| LutatheraLutetium Lu 177 Dotatate, 177Lu-DOTATATE | I–II | 1 | NCT05278208 |
Sorted by most advanced phase and number of active trials. Showing 15 of 29 drugs.
All 35 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Melanoma 352 drugs
- Glioblastoma 245 drugs
- Glioma 184 drugs
- Non-small-cell lung carcinoma 726 drugs
- Brain Neoplasms 190 drugs
- Neuroendocrine tumor 84 drugs
- Neuroblastoma 95 drugs
- Neoplasm 671 drugs
- Metastasis 493 drugs
- Renal cell carcinoma 228 drugs
- Astrocytoma 64 drugs
- Colorectal neoplasm 534 drugs
Broader categories
- Neoplasm 671 drugs
- Glandular and epithelial neoplasm 12 drugs
- Nerve tissue neoplasm 4 drugs
- Urogenital Diseases 16 drugs
- Neuroectodermal tumor 3 drugs
- Neuroepithelial neoplasm 4 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D009373 “Neoplasms, Germ Cell and Embryonal”.